表紙
市場調查報告書
商品編碼
1021659

閹割抗性前列腺癌市場:各療法類型、藥物類別、給藥途徑、流通管道、地區-規模,佔有率,展望,及機會分析(2021年∼2028年)

Castrate-resistant Prostate Cancer Market, by Therapy Type, by Drug Class, by Route of Administration, by Distribution Channel, and By Region - Size, Share, Outlook, and Opportunity Analysis, 2021 - 2028

出版日期: | 出版商: Coherent Market Insights | 英文 167 Pages | 商品交期: 2-3個工作天內

價格
  • 全貌
  • 簡介
  • 目錄
簡介

全球閹割抗性前列腺癌市場,由於市場相關人員的前列腺癌症相關啟發活動,及著重治療的研究開發,產品的銷售和核準,預計促進預測期間的成長。

本報告提供全球閹割抗性前列腺癌市場的相關調查,市場規模和預測,成長及阻礙因素,機會,COVID-19的影響,各療法類型、藥物類別、給藥途徑、流通管道、地區的市場分析,競爭情形,主要企業的簡介等資訊。

目錄

第1章 調查目的、前提條件

第2章 市場概要

  • 報告概要
    • 市場定義和範圍
  • 摘要整理
    • 市場明細:各療法類型
    • 市場明細:各類藥物
    • 市場明細:各給藥途徑
    • 市場明細:各流通管道
    • 市場明細:各地區
  • Coherent Opportunity Map (COM)

第3章 市場動態,法規,及趨勢分析

  • 市場動態
    • 成長要素
    • 阻礙因素
    • 市場機會
  • 影響分析
  • 波特分析
  • 產業趨勢
  • 主要的焦點
  • 流行病學
  • 償付方案
  • 法規方案
  • 產品的銷售與核准
  • 收購與合作方案

第4章 COVID-19影響分析

  • COVID-19流行病學
  • COVID-19對閹割抗性前列腺癌治療的需求與供給的影響
  • COVID-19對醫療保健部門全體的影響

第5章 全球閹割抗性前列腺癌市場:各療法類型(2017-2028)

  • 簡介
  • 荷爾蒙療法
  • 免疫療法
  • 化療

第6章 全球閹割抗性前列腺癌市場:各類藥物(2017-2028)

  • 簡介
  • 抗腫瘤劑
  • 非甾體類抗雄激素
  • 皮質類固醇
  • 微管抑制劑
  • 其他

第7章 全球閹割抗性前列腺癌市場:各給藥途徑(2017-2028)

  • 簡介
  • 口服
  • 注射可能

第8章 全球閹割抗性前列腺癌市場:各流通管道(2017-2028)

  • 簡介
  • 醫院藥局
  • 零售藥局
  • 線上藥局

第9章 全球閹割抗性前列腺癌市場:各地區(2017-2028)

  • 簡介
  • 北美
  • 南美
  • 歐洲
  • 亞太地區
  • 中東
  • 非洲

第10章 競爭情形

  • 企業簡介
    • Sanofi
    • Johnson &Johnson Services Inc.
    • Pfizer Inc.
    • Astellas Pharma Inc.
    • Bayer AG
    • Bristol Myers Squibb
    • Merck Sharp &Dohme
    • Novartis International AG
    • Eli Lilly &Company
    • AstraZeneca plc.
  • 分析師的見解

第11章 Section

目錄

Castration-resistant prostate cancer (CRPC) is a type of advanced prostate cancer that is resistant to testosterone-lowering treatments. Symptoms of mCRPC include: difficulty urinating, pain while passing urine, or blood in the urine, weight loss and shortness of breath. Hormonal therapies are used to treat CRPC such as abiraterone (Zytiga) with corticosteroids inhibit the chemical production of testosterone throughout the body. Zytiga is used in conjunction with prednisone, a powerful anti-inflammatory medication. Other treatments for CRPC include chemo and immunotherapies.

Market Dynamics

Market players are focused on raising awareness campaigns related to prostate cancer, which is expected to fuel growth of the global castrate-resistant prostate cancer market over the forecast period. For instance, on June 17, 2021, patient organization ZERO and Bayer AG, a global life sciences company, collaborated to launch 'We're Not Gonna Take It', a national prostate cancer education program. The campaign encourages men to get screened for prostate cancer and to learn more about risk factors such as family history and elevated prostate-specific antigen (PSA) levels.

Moreover, market players are focusing on product launches and approvals to strengthen their position in the global castrate-resistant prostate cancer market. For instance, on July 30 2019, Bayer AG, a global enterprise, announced that the U.S. Food and Drug Administration (FDA) approved Nubeqa (darolutamide), for the treatment of non-metastatic castration-resistant prostate cancer (nmCRPC).

Furthermore, market players are focusing on research and development activities for the treatment of castrate-resistant prostate cancer, which is expected to drive growth of the global castrate-resistant prostate cancer market. For instance, on April 10 2021, Cardiff Oncology Inc., a clinical-stage biotechnology company in collaboration with scientists at the Massachusetts Institute of Technology's Center for Precision Cancer Medicine (MIT), announced that new gene signature and mechanistic analyses from its ongoing Phase 2 trial of onvansertib in metastatic castrate-resistant prostate cancer (mCRPC) were featured in a virtual oral poster presentation at the American Association for Cancer Research (AACR) Annual Meeting, April, 2021.

Key features of the study:

  • This report provides an in-depth analysis of global castrate-resistant prostate cancer market, provides market size (US$ Billion), and compound annual growth rate (CAGR %) for the forecast period (2021-2028), considering 2020 as the base year.
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrix for this market.
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategies adopted by the leading players
  • It profiles leading players in the global castrate-resistant prostate cancer market based on the following parameters - company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments and strategies, and future plans
  • Key companies covered as a part of this study include Sanofi, Johnson & Johnson Services Inc., Pfizer Inc., Astellas Pharma Inc., Bayer AG, Bristol Myers Squibb, Merck Sharp & Dohme, Novartis International AG, Eli Lilly & Company, and AstraZeneca plc.
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decision regarding their future product launch, technology up-gradation, market expansion, and marketing tactics
  • The global castrate-resistant prostate cancer market report caters to various stakeholders in this industry including investors, suppliers, manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision making through various strategy matrices used in analyzing the global castrate-resistant prostate cancer market.

Detailed Segmentation:

  • Global Castrate-resistant Prostate Cancer Market, By Therapy Type:
  • Hormonal Therapy
  • Immunotherapy
  • Chemotherapy
  • Global Castrate-resistant Prostate Cancer Market, By Drug Class:
  • Antineoplastic
  • Non-steroidal Antiandrogen
  • Corticosteroids
  • Microtubule Inhibitor
  • Others
  • Global Castrate-resistant Prostate Cancer Market, By Route of Administration:
  • Oral
  • Injectable
  • Global Castrate-resistant Prostate Cancer Market, By Distribution Channel:
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • Global Castrate-resistant Prostate Cancer Market, By Region:
  • North America
  • By Therapy Type:
  • Hormonal Therapy
  • Immunotherapy
  • Chemotherapy
  • By Drug Class:
  • Antineoplastic
  • Non-steroidal Antiandrogen
  • Corticosteroids
  • Microtubule Inhibitor
  • Others
  • By Route of Administration:
  • Oral
  • Injectable
  • By Distribution Channel:
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • By Country:
  • U.S.
  • Canada
  • Latin America
  • By Therapy Type:
  • Hormonal Therapy
  • Immunotherapy
  • Chemotherapy
  • By Drug Class:
  • Antineoplastic
  • Non-steroidal Antiandrogen
  • Corticosteroids
  • Microtubule Inhibitor
  • Others
  • By Route of Administration:
  • Oral
  • Injectable
  • By Distribution Channel:
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • By Country:
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America
  • Europe
  • By Therapy Type:
  • Hormonal Therapy
  • Immunotherapy
  • Chemotherapy
  • By Drug Class:
  • Antineoplastic
  • Non-steroidal Antiandrogen
  • Corticosteroids
  • Microtubule Inhibitor
  • Others
  • By Route of Administration:
  • Oral
  • Injectable
  • By Distribution Channel:
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • By Country:
  • U.K.
  • Germany
  • Italy
  • Spain
  • France
  • Russia
  • Rest of Europe
  • Asia Pacific
  • By Therapy Type:
  • Hormonal Therapy
  • Immunotherapy
  • Chemotherapy
  • By Drug Class:
  • Antineoplastic
  • Non-steroidal Antiandrogen
  • Corticosteroids
  • Microtubule Inhibitor
  • Others
  • By Route of Administration:
  • Oral
  • Injectable
  • By Distribution Channel:
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • By Country
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • ASEAN
  • Rest of Asia Pacific
  • Middle East
  • By Therapy Type:
  • Hormonal Therapy
  • Immunotherapy
  • Chemotherapy
  • By Drug Class:
  • Antineoplastic
  • Non-steroidal Antiandrogen
  • Corticosteroids
  • Microtubule Inhibitor
  • Others
  • By Route of Administration:
  • Oral
  • Injectable
  • By Distribution Channel:
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • By Country:
  • GCC
  • Israel
  • Rest of Middle East
  • Africa
  • By Therapy Type:
  • Hormonal Therapy
  • Immunotherapy
  • Chemotherapy
  • By Drug Class:
  • Antineoplastic
  • Non-steroidal Antiandrogen
  • Corticosteroids
  • Microtubule Inhibitor
  • Others
  • By Route of Administration:
  • Oral
  • Injectable
  • By Distribution Channel:
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • By Country/Region:
  • South Africa
  • Central Africa
  • North Africa
  • Company Profiles
    • Sanofi*
  • Company Overview
  • Product Portfolio
  • Financial Performance
  • Recent Developments/Updates
  • Strategies
    • Johnson & Johnson Services Inc.
    • Pfizer Inc.
    • Astellas Pharma Inc.
    • Bayer AG
    • Bristol Myers Squibb
    • Merck Sharp & Dohme
    • Novartis International AG
    • Eli Lilly & Company
    • AstraZeneca plc.

* marked represents similar segmentation in other categories in the respective section.

Table of Contents

1. Research Objectives and Assumptions

  • Research Objectives
  • Assumptions
  • Abbreviations

2. Market Overview

  • Report Description
    • Market Definition and Scope
  • Executive Summary
    • Market Snippet, By Therapy type
    • Market Snippet, By Drug Class
    • Market Snippet, By Route of Administration
    • Market Snippet, By Distribution Channel
    • Market Snippet, By Region
  • Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

  • Market Dynamics
    • Drivers
    • Restraints
    • Market Opportunities
  • Impact Analysis
  • Porter's Analysis
  • Industry Trends
  • Key Highlights
  • Epidemiology
  • Reimbursement Scenario
  • Regulatory Scenario
  • Product Launch and Approvals
  • Acquisition and Collaboration Scenario

4. COVID - 19 Impact Analysis

  • COVID-19 Epidemiology
  • Impact of COVID-19 on Demand and Supply of Castrate-Resistant Prostate Cancer Treatment
  • Impact of COVID-19 on the overall Healthcare Sector

5. Global Castrate-resistant Prostate Cancer Market, By Therapy Type, 2017-2028 (US$ Billion)

  • Introduction
    • Market Share Analysis, 2021 and 2028 (%)
    • Y-o-Y Growth Analysis, 2018 - 2028
    • Segment Trends
  • Hormonal Therapy
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Billion)
  • Immunotherapy
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Billion)
  • Chemotherapy
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Billion)

6. Global Castrate-resistant Prostate Cancer Market, By Drug Class, 2017 - 2028 (US$ Billion)

  • Introduction
    • Market Share Analysis, 2021 and 2028 (%)
    • Y-o-Y Growth Analysis, 2018 - 2028
    • Segment Trends
  • Antineoplastic
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Billion)
  • Non-steroidal Antiandrogen
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Billion)
  • Corticosteroids
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Billion)
  • Microtubule Inhibitor
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Billion)
  • Others
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Billion)

7. Global Castrate-resistant Prostate Cancer Market, By Route of Administration, 2017 - 2028 (US$ Billion)

  • Introduction
    • Market Share Analysis, 2021 and 2028 (%)
    • Y-o-Y Growth Analysis, 2018 - 2028
    • Segment Trends
  • Oral
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Billion)
  • Injectable
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Billion)

8. Global Castrate-resistant Prostate Cancer Market, By Distribution Channel, 2017 - 2028 (US$ Billion)

  • Introduction
    • Market Share Analysis, 2021 and 2028 (%)
    • Y-o-Y Growth Analysis, 2018 - 2028
    • Segment Trends
  • Hospital Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Billion)
  • Retail Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Billion)
  • Online Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Billion)

9. Global Castrate-resistant Prostate Cancer Market, By Region, 2017 - 2028 (US$ Billion)

  • Introduction
    • Market Share Analysis, By Region, 2021 and 2028 (%)
    • Y-o-Y Growth Analysis, For Regions, 2018 - 2028
    • Regional Trends
  • North America
    • Market Size and Forecast, By Therapy Type, 2017 - 2028 (US$ Bn)
    • Market Size and Forecast, By Drug Class, 2017 - 2028 (US$ Bn)
    • Market Size and Forecast, By Route of Administration, 2017 - 2028 (US$ Bn)
    • Market Size and Forecast, By Distribution Channel, 2017 - 2028 (US$ Bn)
    • Market Size and Forecast, By Country, 2017 - 2028 (US$ Bn)
    • U.S.
    • Canada
  • Latin America
    • Market Size and Forecast, By Therapy Type, 2017 - 2028 (US$ Bn)
    • Market Size and Forecast, By Drug Class, 2017 - 2028 (US$ Bn)
    • Market Size and Forecast, By Route of Administration, 2017 - 2028 (US$ Bn)
    • Market Size and Forecast, By Distribution Channel, 2017 - 2028 (US$ Bn)
    • Market Size and Forecast, By Country, 2017 - 2028 (US$ Bn)
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
  • Europe
    • Market Size and Forecast, By Therapy Type, 2017 - 2028 (US$ Bn)
    • Market Size and Forecast, By Drug Class, 2017 - 2028 (US$ Bn)
    • Market Size and Forecast, By Route of Administration, 2017 - 2028 (US$ Bn)
    • Market Size and Forecast, By Distribution Channel, 2017 - 2028 (US$ Bn)
    • Market Size and Forecast, By Country, 2017 - 2028 (US$ Bn)
    • Germany
    • U.K.
    • France
    • Italy
    • Spain
    • Russia
    • Rest of Europe
  • Asia Pacific
    • Market Size and Forecast, By Therapy Type, 2017 - 2028 (US$ Bn)
    • Market Size and Forecast, By Drug Class, 2017 - 2028 (US$ Bn)
    • Market Size and Forecast, By Route of Administration, 2017 - 2028 (US$ Bn)
    • Market Size and Forecast, By Distribution Channel, 2017 - 2028 (US$ Bn)
    • Market Size and Forecast, By Country, 2017 - 2028 (US$ Bn)
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
  • Middle East
    • Market Size and Forecast, By Therapy Type, 2017 - 2028 (US$ Bn)
    • Market Size and Forecast, By Drug Class, 2017 - 2028 (US$ Bn)
    • Market Size and Forecast, By Route of Administration, 2017 - 2028 (US$ Bn)
    • Market Size and Forecast, By Distribution Channel, 2017 - 2028 (US$ Bn)
    • Market Size and Forecast, By Country, 2017 - 2028 (US$ Bn)
    • GCC
    • Israel
    • Rest of Middle East
  • Africa
    • Market Size and Forecast, By Therapy Type, 2017 - 2028 (US$ Bn)
    • Market Size and Forecast, By Drug Class, 2017 - 2028 (US$ Bn)
    • Market Size and Forecast, By Route of Administration, 2017 - 2028 (US$ Bn)
    • Market Size and Forecast, By Distribution Channel, 2017 - 2028 (US$ Bn)
    • Market Size and Forecast, By Country/Region, 2017 - 2028 (US$ Bn)
    • South Africa
    • Central Africa
    • North Africa

10. Competitive Landscape

  • Company Profiles
    • Sanofi*
  • Company Overview
  • Product Portfolio
  • Financial Performance
  • Recent Developments/Updates
  • Strategies
    • Johnson & Johnson Services Inc.
    • Pfizer Inc.
    • Astellas Pharma Inc.
    • Bayer AG
    • Bristol Myers Squibb
    • Merck Sharp & Dohme
    • Novartis International AG
    • Eli Lilly & Company
    • AstraZeneca plc.

Key pointers provided are also applicable to other companies covered in the scope of the report.

  • Analyst Views

11. Section

  • Research Methodology
  • About us
  • Contact